The next Bionews event is coming soon!
Webinar • 1 hour
In rare diseases, most of what we think we know about patients, and how we act on it, is really just assumptions: personas built from anecdotes, strategies borrowed from mass-market
Webinar + Q&A • 1 hour
The evidence landscape is shifting in ways that most 2024-era RWE programs were not designed to capture. Patient communities are generating structured, continuous signals about treatment experience, trust, and unmet
Webinar + Q&A • 1 hour
Real-world evidence has transformed how pharma teams evaluate treatments, design trials, and build engagement strategies. Claims data, EHRs, and PROs have become essential to pharma decision-making. But they tell us
